Mucosal immune responses to chimeric papillomavirus like particles in mice

Liu, Xiao Song. (2001). Mucosal immune responses to chimeric papillomavirus like particles in mice PhD Thesis, Department of Medicine, The University of Queensland.

       
Attached Files (Some files may be inaccessible until you login with your UQ eSpace credentials)
Name Description MIMEType Size Downloads
THE16988.pdf Full text application/pdf 8.33MB 4
Author Liu, Xiao Song.
Thesis Title Mucosal immune responses to chimeric papillomavirus like particles in mice
School, Centre or Institute Department of Medicine
Institution The University of Queensland
Publication date 2001-07
Thesis type PhD Thesis
Supervisor Prof Ian H. Frazer
Dr. Graham Leggatt
Dr Jian Zhou
Total pages 196
Collection year 2003
Language eng
Subjects L
320402 Medical Virology
730102 Immune system and allergy
Formatted abstract
AIM: Chimeric papillomavirus virus like particles (PV VLPs) has been proposed as a novel antigen delivery system that combines both antigen and adjuvant properties. I wished to compare their efficacy at inducing systemic and mucosal immune responses after systemic and mucosal delivery.

Methods: (Chapter 2): Various PV L1 chimeric capsid proteins including chimeric BPV1L1 incorporating an HPV16E7 H-2d CTL epitope (L1E7), chimeric BPVL1 incorporating a HIVIIIb P18I10 CTL epitope (L1P18), chimeric BPVL1 VLPs incorporating a HIVIIIb V3 loop polypeptide (L1V3) and a series of chimeric HPV6bLlVLPs incorporating HIV tat, rev and SIV p27 sequences were expressed in a baculovirus expression system. Humoral and cellular immune responses, especially mucosal and systemic responses following various mucosal delivery routes were examined in chimeric PV VLP immunised mice. The immune responses induced by PV VLPs were measured as serum and mucosal antibody responses to LI and incorporated protein, and systemic and local mucosal CTL responses by using 51Cr release assay or the INF-γ secreting ELISPOT assay.

Results: The following observations were made:
1, Chimeric PV VLPs, when delivered mucosally in the absence of any adjuvants, can elicit both mucosal as well as systemic immune responses to PV LI and to incorporated antigenic peptide, although the systemic immune responses are weaker than that from systemic immunised mice (Chapter 4 and chapter 5).
2, Intranasal and intrarectal administration is more effective at inducing mucosal immune responses than intravaginal administration (Chapter 4 and chapter 5).
3, Not all chimeric VLP constructs produce VLPs, however, sub VLP particles can be immunogenic (Chapter 3).
4. Prior immunisation with VLPs affects subsequent responses to new epitopes introduced into the VLPs (Chapter 6).

Conclusions and future directions: From these data it can be concluded that
1, chimeric PV VLPs are a potential vaccine antigen delivery system for inducing both prophylactic and therapeutic immunity to viruses at mucosal surfaces.
2, construction of immunogenic chimeric VLPs remains an empiric technique.
3, prior immunity to VLPs will impact on their utility as a vaccine delivery system. Future studies will explore the molecular and cellular mechanisms ley which prior immunity to VLPs inhibits responses to new epitopes.

Keyword Papillomavirus diseases
Papillomavirus diseases -- Immunotherapy
Additional Notes missing page VIII

Document type: Thesis
Collection: UQ Theses (RHD) - UQ staff and students only
 
Citation counts: Google Scholar Search Google Scholar
Created: Fri, 24 Aug 2007, 17:50:08 EST